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Abstract
Background: Only a few studies have investigated non-malignant respiratory effects of glass
microfibers and these have provided inconsistent results. Our objective was to assess the effects
of exposure to glass microfibers on respiratory and skin symptoms, asthma and lung function.
Methods: A cross-sectional study of 102 workers from a microfiber factory (response rate 100%)
and 76 office workers (73%) from four factories in Thailand was conducted. They answered a
questionnaire on respiratory health, occupational exposures, and lifestyle factors, and performed
spirometry. Measurements of respirable dust were available from 2004 and 2005.
Results: Workers exposed to glass microfibers experienced increased risk of cough (adjusted OR
2.04), wheezing (adjOR 2.20), breathlessness (adjOR 4.46), nasal (adjOR 2.13) and skin symptoms
(adjOR 3.89) and ever asthma (adjOR 3.51), the risks of breathlessness (95%CI 1.68–11.86) and
skin symptoms (1.70–8.90) remaining statistically significant after adjustment for confounders.
There was an exposure-response relation between the risk of breathlessness and skin symptoms
and increasing level of microfiber exposure. Workers exposed to sensitizing chemicals, including
phenol-formaldehyde resin, experienced increased risk of cough (3.43, 1.20–9.87) and nasal
symptoms (3.07, 1.05–9.00).
Conclusion: This study provides evidence that exposure to glass microfibers increases the risk of
respiratory and skin symptoms, and has an exposure-response relation with breathlessness and
skin symptoms. Exposure to sensitizing chemicals increased the risk of cough and nasal symptoms.
The results suggest that occupational exposure to glass microfibers is related to non-malignant
adverse health effects, and that implementing exposure control measures in these industries could
protect the health of employees.
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Background
Glass microfiber is a microfiber produced from glass at
high temperature using a melting and fiberising process. It
is one of the man-made vitreous fibers (MMVF), which are
non-crystalline or vitreous in molecular structure [1] and
widely used for thermal and acoustic insulation. The
diameter of a microfiber is in the range of 0.2–4 μm [2].
Asbestos is a naturally occurring fiber that has been widely
used for insulation and reinforcement of other materials.
However, it is known to cause pleural diseases, lung fibro-
sis, lung cancer, mesothelioma, and chronic bronchitis in
exposed workers [1,3]. Man-made synthetic fibers have
been developed with the aim to reduce the asbestos-
related health risks.
MMVF have been thought to cause fewer health problems
than asbestos, but these have not been studied as exten-
sively. Studies have suggested that glass fibers are possibly
carcinogenic to humans [4,5], but recent reviews are cau-
tious in making conclusions, because there is not enough
evidence from human studies, so the conclusions are
based mainly on evaluation of animal toxicology and
mechanisms [1,6,7]. There are even fewer studies on
potential non-carcinogenic respiratory effects of glass fib-
ers [6,8,9] and these have provided inconsistent results.
There is more consistent evidence of occurrence of skin
diseases in glass fiber workers [10,11]. However, we were
able to identify only one previous epidemiological study
assessing the risk of skin symptoms related to occupa-
tional exposures in such industry [12].
Clinical practitioners and policy makers frequently face
the question, whether there could be adverse health
effects from exposure to glass microfibers. Because of the
controversy concerning non-malignant health effects, we
studied employees in a glass microfiber company in Thai-
land. Figure 1 shows the process of production. The proc-
ess starts by preparing the raw materials, which include
glass, feldspar, soda ash, and sand, for making molten
glass, and by mixing chemicals, including sulfuric acid
(H2SO4), phenol, sodium hydroxide (NaOH), and forma-
lin, for making resin. A mixture of ammonium sulfate,
mineral oil and silane is blended with resin to make a
binder. The binder is transferred in a closed pump-oper-
ated tube to the fiberising machine. Glass is melted in a
kiln and spun into microfibers, onto which the resin-
binder is sprayed to strengthen the fibers. After that the
coated microfibers are heated in a furnace in high temper-
ature (1400–1600°C) to cure the resin and make sheets of
fiber. In the final process the microfiber sheets are cut into
the right size and wrapped in an aluminum foil. The qual-
ity of the microfiber sheets is checked before sending to
customers. Exposure to microfibers of the workers occurs
via two routes: by inhaling and by direct contact with the
skin.
The aim of this study was to investigate the relations of
occupational exposure to glass microfibers to respiratory
and skin symptoms, asthma and spirometric lung func-
tion. Potential health effects related to exposure to sensi-
tizers used in the process were also addressed.
Methods
Study design
A cross-sectional study was performed among employees
of a glass microfiber production company and office
workers from four companies in Thailand from Septem-
ber through December 2006. The study was approved by
the ethics committee of the Faculty of Public Health at the
Mahidol University, Thailand. Each participant gave an
informed consent.
Study population
All 102 workers of a microfiber factory (response rate
100%) participated in the study, including 14 workers
preparing and mixing raw materials and chemicals, 15
furnace and fiberising process workers, 14 workers cutting
fiber sheets, 35 packing workers, 10 warehouse workers, 5
quality control staff and 9 maintenance workers. Alto-
gether 76 office workers (response rate 73%) from four
factories formed the unexposed control population,
including 18 from the microfiber factory, 24 from a milk
powder factory, 18 from a wood furniture factory and 16
from a tile factory [13,14]. Office workers were managers,
other administrative staff, chauffeurs, and security staff
checking identification cards at the gates.
Measurement methods
Questionnaire
A questionnaire on respiratory health was modified from
the Finnish Environment and Asthma Study [15-20]. It
inquired about personal characteristics, health informa-
tion, smoking and exposure to secondhand smoke (SHS)
at home and at work, occupation, exposures in the work
environment, and exposures in the home environment.
The questionnaire was translated into Thai and then back-
translated into English to ensure the accuracy of the trans-
lation.
Lung function tests
All participants performed spirometry following the
standards by the American Thoracic Society [21] with a
Minato Autospiro PAL spirometer (Minato Medical Sci-
ences Ltd, Osaka, Japan). The best forced expiratory vol-
ume in 1 second (FEV1) and forced vital capacity (FVC)
out of a minimum of three acceptable forced expirations
were used as outcomes. FEV1 and FVC as percentage (%)
of predicted were calculated based on reference values
from a healthy non-smoking Thai population [22].Environmental Health 2009, 8:36 http://www.ehjournal.net/content/8/1/36
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Air measurements
The concentrations of respirable dust had been measured
in the air of different factory areas by the gravimetric anal-
ysis method (NIOSH method 0600) in 2004 and 2005 by
an independent consulting company [23]. Aluminum
cyclones were used for 6 hours at the flow rate 2.5 l/min.
Two environmental samples were taken in each area to get
the average concentration. The concentrations of different
chemicals, including NaOH, phenol, ammonia, formal-
dehyde and H2SO4 had also been measured by standard
NIOSH methods [23]. There had not been any changes in
the industrial processes or environmental control meas-
ures between 2004–5 and our data collection in 2006.
Outcome assessment
The outcomes of interest included the occurrence of respi-
ratory and skin symptoms in the past 12 months and the
occurrence of asthma currently and ever. The symptoms
included cough, phlegm production, wheezing, breath-
lessness, nasal symptoms, eye symptoms and skin symp-
toms, and they as well as asthma were defined based on
answers to the questionnaire (Table 1).
Lung function outcomes included the best values of FEV1,
FVC, FEV1 % of predicted and FVC % of predicted.
Processes of glass microfiber production Figure 1
Processes of glass microfiber production.
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Exposure assessment
Occupational exposure to glass microfibers was the main
exposure of interest. This was assessed in two ways: 1)
based on working as a factory worker (coded 1) or an
office worker (coded 0, the reference category), and 2) fac-
tory workers were grouped into two exposure categories
reflecting the level of microfiber exposure based on their
job title and measurements of air respirable microfiber
dust. High exposure group (n = 64) consisted of those
working in the fiberising process, furnace, cutting and
packing. Low exposure group (n = 38) consisted of those
working in the raw material preparation, warehouse,
maintenance, and quality control. These were compared
to office workers forming the unexposed reference cate-
gory.
Some factory workers had exposure to potentially sensitiz-
ing chemicals, such as formaldehyde, phenol resin and
mineral oils (Figure 1), so we also analyzed separately
potential effects related to exposure to any sensitizing
chemical. The population was categorized into those hav-
ing any exposure to sensitizers (n = 19) (coded 1), includ-
ing material preparation and quality control staff, and
into those with no exposure to sensitizers (n = 159)
(coded 0), including the other factory as well as office
workers.
Data analysis
Odds ratios (OR) and 95% confidence intervals (95% CI)
were calculated to quantify the relations between the
exposures of interest and the occurrence of symptoms and
asthma. All analyses were performed by SPSS statistical
program, version 14. A model was fitted for each symp-
tom outcome and for each type of exposure separately. All
models adjusted for sex, age, educational level, smoking
status (currently, formerly, never), and exposure to SHS at
home and/or at work in multivariate logistic regression.
Linear regression analyses were used to estimate the rela-
tions between exposures of interest and lung function out-
comes. A separate model was fitted for each lung function
outcome and for each type of exposure separately. Age,
sex, height, educational level, and smoking were adjusted
for as potential confounders when studying FEV1 and
FVC levels as outcomes, while FEV1 % predicted and FVC
% predicted were already controlled for sex, age and
height by the prediction equations.
Results
Characteristics and symptoms of the study population
Additional file 1 shows the characteristics of the study
population. The population consisted of 123 males
(69%) and 55 females (31%). The occurrence of upper
and lower respiratory and skin symptoms and asthma are
presented in table 2. Factory workers experienced about
twice as much cough, breathlessness, nasal symptoms,
and skin symptoms as office workers. The prevalence of
wheezing and asthma were slightly higher in factory work-
ers.
Air measurements
Air concentrations of respirable dust had been monitored
in the factory in 2004 and 2005 (Table 3), the major com-
ponent of this being glass microfibers. The concentrations
were 0.07–1.70 mg/m3. The fiberising and furnace areas
showed the highest mean concentration (1.70 mg/m3 in
2005), while corridors (0.07 mg/m3) and warehouse area
(0.31 mg/m3) had the lowest mean concentrations. Con-
Table 1: Definitions of symptoms and asthma used as outcomes
Symptoms/conditions Definition
Cough Recurrent or prolonged cough
Phlegm production Recurrent or prolonged phlegm production
Wheezing Wheezing or whistling of the chest
Breathlessness Chest tightness or difficulty breathing
Nasal symptoms Dryness, itching or smarting of nose, stuffy nose, runny nose or repeated sneezing (apart from colds)
Eye symptoms Dryness of eyes, itchy eyes, irritation or smarting of eyes, watering of eyes, or redness of eyes
Skin symptoms Dryness or flaking of skin, itchy skin, irritation, smarting or redness of skin, sore or tender skin, or urticaria
Current asthma Asthma diagnosed by a physician in the past 12 months
Asthma ever Asthma diagnosed by a physician ever during life timeEnvironmental Health 2009, 8:36 http://www.ehjournal.net/content/8/1/36
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centrations of other chemicals (mentioned in the meth-
ods) were in general low, with the exception that high
concentration of ammonia had been measured in the
fiberising process (3.48 mg/m3) and cutting (4.07 mg/m3)
areas.
Effects of glass microfibers and sensitizing chemicals on 
symptoms and asthma
The crude OR of cough (2.85, 95% CI 1.38–5.86), breath-
lessness (3.80, 1.83–7.92), nasal symptoms (2.06, 95%
CI 1.08–3.91), and skin symptoms (3.45, 95% CI 1.83–
6.49) were significantly increased in factory workers com-
pared to office workers, while the OR of phlegm produc-
tion and eye symptoms did not show any relation to
factory work (Table 4). After adjusting for confounders,
the ORs of breathlessness and skin symptoms remained
significant (4.46, 1.68–11.86 and 3.89, 1.70–8.90, respec-
tively). Adjusted OR of cough (2.04), wheezing (2.20),
nasal symptoms (2.13) and ever asthma (OR 3.51) were
also increased, but did not reach statistical significance.
There were no subjects with current asthma among office
workers, so the risk for this outcome could not be esti-
mated.
Table 5 presents adjusted ORs according to the level of
exposure to glass microfibers. Both low and high expo-
sures were related to significantly increased risk of breath-
lessness (adjusted OR 3.94, 95% CI 1.33–11.71, and 5.08,
1.69–15.23, respectively) and skin symptoms (2.99,
1.13–7.91, and 4.82, 1.89–12.33, respectively), the trend
suggesting exposure-response relation. The ORs of wheez-
ing, nasal symptoms and asthma ever were increased,
although not statistically significant. The risk of these
symptoms did not show any obvious exposure-response
relation.
Table 5 also shows adjusted ORs in relation to exposure to
any sensitizers. Such exposure was related to significantly
increased risk of cough (3.43, 95% CI 1.20–9.87) and
nasal symptoms (3.07, 1.05–9.00). The risk of breathless-
ness was also increased (2.84, 0.99–8.12), although it did
not reach statistical significance.
Effects of glass microfibers and sensitizers on lung function
No significant deficits in lung function were detected in
relation to glass microfiber or sensitizer exposure,
although small deficits were seen in FEV1 and FEV1 %
predicted in the high microfiber exposure group (Table 6).
Discussion
Glass microfiber is one of the synthetic man-made vitre-
ous fibers that are widely used for insulation. Because of
the controversy concerning potential non-malignant
health effects of glass microfibers, we studied workers in a
factory producing glass microfiber sheets in Thailand. Fac-
tory workers experienced increased risk of cough, wheez-
ing, breathlessness, nasal symptoms, skin symptoms and
ever asthma compared to office workers. After adjusting
for potential confounders, the risk of breathlessness and
skin symptoms remained significantly increased, and the
risk of both of these symptoms showed a trend suggesting
exposure-response relation with increasing glass micro-
fiber exposure level. Interestingly, these effects were
detected at concentrations of respirable dust, consisting
mainly of glass microfibers, that were below the threshold
limit value for respirable dust of 3 mg/m3.
Table 2: Occurrence of respiratory and skin symptoms and 
asthma in factory and office workers
Office workers
N = 76
Factory workers
N = 102
Symptom/condition n % n %
Prolonged cough 13 17.1 37 36.3
Phlegm production 24 31.6 29 28.4
Wheezing 9 11.8 15 14.7
Breathlessness 12 15.8 42 41.2
Nasal symptoms 21 27.6 44 43.1
Eye symptoms 23 30.3 27 26.5
Skin symptoms 23 30.3 61 59.8
Asthma ever 3 3.9 6 5.9
Current asthma 0 0 5 4.9
Table 3: Mean concentration of respirable dust (mg/m3) in 
different work areas
Area 2004 2005
Material preparation area 0.86 0.35
Fiberising and furnace area - 1.70
Cutting area 1.52 0.50
Packing area 1.26 -
Warehouse area 0.31 -
Corridors - 0.07
- means no measurements availableEnvironmental Health 2009, 8:36 http://www.ehjournal.net/content/8/1/36
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Table 4: Odd ratios (OR) of respiratory and skin symptoms and asthma in relation to exposure to glass microfibers in factory workers 
compared to office workers
All factory workers*
N = 102
All factory workers*
N = 102
Symptom/Disease Crude OR 95% CI Adjusted OR† 95% CI
Cough 2.85 1.38–5.86 2.04 0.83–4.97
Phlegm 0.84 0.44–1.61 0.80 0.35–1.82
Wheezing 1.26 0.52–3.07 2.20 0.61–7.90
Breathlessness 3.80 1.83–7.92 4.46 1.68–11.86
Nasal 2.06 1.08–3.91 2.13 0.89–5.05
Eye 0.85 0.44–1.65 0.92 0.41–2.11
Skin 3.45 1.83–6.49 3.89 1.70–8.90
Asthma ever 1.52 0.37–6.29 3.51 0.29–55.99
*Office workers formed the reference category (OR = 1)
†Adjusted for sex, age, education, smoking, and exposure to SHS at work and/or at home
Table 5: Adjusted odd ratios (OR) of respiratory and skin symptoms and asthma in relation to the level of microfiber exposure and 
exposure to sensitizing chemicals
Low MF level*
N = 38
High MF level*
N = 64
Exposure to any sensitizer†
N = 19
Symptom/Disease Adjusted OR‡ 95% CI Adjusted OR‡ 95% CI Adjusted OR‡ 95% CI
Cough 1.72 0.61–4.88 2.34 0.87–6.31 3.43 1.20–9.87
Phlegm 0.55 0.20–1.52 1.08 0.42–2.76 0.61 0.19–1.92
Wheezing 2.38 0.58–9.79 2.00 0.46–8.70 1.28 0.30–5.50
Breathlessness 3.94 1.33–11.71 5.08 1.69–15.23 2.84 0.99–8.12
Nasal 2.01 0.74–5.44 2.25 0.84–6.00 3.07 1.05–9.00
Eye 0.73 0.26–2.02 1.11 0.44–2.83 0.91 0.30–2.78
Skin 2.99 1.13–7.91 4.82 1.89–12.33 1.95 0.65–5.80
Asthma ever 3.48 0.18–66.84 3.52 0.21–58.07 1.41 0.12–16.38
*Office workers formed the reference category (OR = 1)
†Compared to office workers and factory workers with no exposure to sensitizers (OR = 1 in this reference category)
‡Adjusted for sex, age, education, smoking, and exposure to SHS at work and/or at home
MF = glass microfiber exposureEnvironmental Health 2009, 8:36 http://www.ehjournal.net/content/8/1/36
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The respiratory and skin effects observed could be due to
an irritant mechanism by glass microfibers. Lack of effect
on spirometric lung function would be consistent with an
irritant effect. A review by the World Health Organization
(WHO) suggested that MMVF can cause transient irrita-
tion of skin, eyes and upper airways, but that there has
been so far insufficient evidence of effects on lower air-
ways [24]. In our study, the risks of wheezing (adjusted
OR 2.20) and asthma (adjusted OR 3.51) were also
increased, although not statistically significantly, which
raises the question whether exposure to glass microfibers
could induce an irritant-type of asthma [25]. Our study is
not able to answer this question definitely, because of the
small number of asthmatics in our study population.
Abbate and co-workers [26] investigated 29 men
employed in glass fiber reinforced plastic processing with
a clinical check-up and bronchoalveolar lavage (BAL).
Microscopic and biochemical analyses of BAL fluid sug-
gested that oxidative stress activates an inflammatory
process in the airways as a consequence of exposure to
glass fibers.
Some processes of the glass microfiber production involve
working with potential sensitizers, such as formaldehyde.
Exposure to sensitizing chemicals was associated with sig-
nificantly increased risks of cough and nasal symptoms.
The risk of breathlessness was also increased, but no obvi-
ous effect on skin symptoms was detected. Exposure to
sensitizing chemicals did not affect adversely spirometric
lung function or the risk of asthma, but these conclusions
have to be cautious because of the small number of work-
ers with sensitizer exposure (n = 19).
Validity issues
The small sample size of office workers is a limitation of
this study. The number of subjects that could be studied
was dependent on access to workforces, a problem com-
monly encountered in occupational epidemiology. To
counterbalance this limitation, we made efforts to get
good response rates and succeeded in this well. The
response rate was 100% among glass microfiber factory
workers currently employed at the factory and it was also
relatively good at 73% among office workers, so selection
bias is not likely to explain our results.
The outcome assessment in this study was based on self-
report of symptoms and doctor-diagnosed asthma and
measurements of lung function. All of these investigations
were carried out in the same way in factory and office
workers. The same protocol for the questionnaire and
spirometry was applied in all four factories, where office
workers were recruited to form the control group. It is pos-
sible that our study underestimates to some extent the
true effects of glass microfiber exposure because of the
cross-sectional study design. It has previously been esti-
mated that about 5% of workers involved in MMVF pro-
duction leave employment because of problems of skin
irritation [2], meaning that those staying in the industry
are likely to be selected based on better health. Our find-
ing that vital capacity was actually somewhat better in fac-
tory workers than in office workers supports the
possibility of some 'healthy worker' selection taking place.
A small number of asthmatics, especially current asthmat-
ics among office workers, is a limitation of the study, as
the results suggested increased risk of ever asthma in rela-
tion to glass microfiber exposure, but this did not reach
statistical significance. The rather small number detected
also among factory workers, although the risk of wheezing
Table 6: Adjusted effects on lung function related to exposure to glass microfibers in all factory workers, by the level of microfiber 
exposure and exposure to sensitizing chemicals
Lung function parameter All factory workers‡
N = 102
Low MF level‡
N = 38
High MF level‡
N = 64
Exposure to any sensitizer§
N = 19
β 95% CI β 95% CI β 95% CI β 95% CI
FEV1* (liter) 0.05 -0.10 to 0.20 0.13 -0.04 to 0.31 -0.01 -0.18 to 0.15 0.24 0.04 to 0.43
FVC* (liter) 0.14 -0.02 to 0.30 0.19 -0.007 to 0.38 0.10 -0.07 to 0.29 0.29 0.08 to 0.50
FEV1%pred† 1.20 -3.35 to 5.75 2.68 -2.74 to 8.11 -0.05 -5.24 to 5.14 4.64 -1.53 to 10.80
FVC%pred† 1.81 -2.33 to 5.94 1.85 -3.09 to 6.79 1.77 -2.95 to 6.49 4.37 -1.23 to 9.98
* Effect estimates adjusted for sex, age, height, education, and smoking
†Effect estimates adjusted for education and smoking. The predicted values controlled for age and height. They were calculated separately for men 
and women
‡Compared to office workers (OR = 1 in this reference category).
§Compared to office workers and factory workers with no exposure to sensitizers (OR = 1 in this reference category)
MF = glass microfiber exposureEnvironmental Health 2009, 8:36 http://www.ehjournal.net/content/8/1/36
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was increased, may reflect the health care system. Workers
may not seek medical help for their asthma-type symp-
toms because of fear of losing their job.
Exposure assessment was based on job title comple-
mented by air respirable dust measurements from 2004
and 2005. There had not been any changes in the indus-
trial processes or environmental control measures
between these years and our data collection in 2006, so
the air measurements are likely to reflect well the relevant
exposure situation in the factory. These methods give a
rough estimate of microfiber exposure level, which ena-
bled us to compare high and low exposure groups. The
unexposed control group (i.e. office workers) was formed
of those working for the companies, but not working in
the production areas, packing areas, warehouse or quality
control, i.e. not having any major exposures. However,
the managers sometimes visited the process for short peri-
ods of time. During these visits they were required to wear
protective masks. It is possible that some of them could
have had small amount of exposure, which could cause
some underestimation of the true effects of glass micro-
fiber exposure.
The number of workers exposed to sensitizing chemicals
was small (n = 19), but such exposure showed significant
associations with cough and nasal symptoms. Sensitizer
exposure was related to a somewhat different symptom
pattern than glass microfiber exposure, but most of those
exposed to sensitizers were also exposed to microfibers, so
we were not able to disentangle their effects sharply.
We collected data on many potential confounders in our
questionnaire, including personal characteristics (sex,
age), genetic background (parental atopy or asthma),
socio-economic status (education), lifestyle habits (smok-
ing), and other risk factors at work (SHS exposure, stress
at work) and at home (pet keeping). We addressed all of
these and controlled for the factors that were important
potential confounders in the multivariate regression mod-
els in order to exclude them as potential explanations for
our findings.
Synthesis with previous knowledge
Only a few previous studies have been reported on non-
cancer respiratory effects of glass fibers and they have pro-
vided inconsistent results. According to reviews there has
been insufficient evidence to make any firm conclusions
[6], so more studies on this topic in human subjects are
needed.
In the only previous epidemiological study on respiratory
effects, Moulin and co-workers [9] investigated 2,024 men
from three plants manufacturing glass wool and two man-
ufacturing rock wool in France. In the biggest plant stud-
ied, exposure to fibers was related to significantly
increased risk of cough, phlegm, dyspnea and pharynx-
larynx symptoms, ORs being 1.6–6.0. However, no effects
were detected in the other four factories. Working in resin
preparation was consistently related to the risk of phar-
ynx-larynx symptoms. Thus, the findings in the largest fac-
tory are consistent with our findings.
Results of three clinical studies on non-malignant respira-
tory effects in workers exposed to glass fibers are partly
compatible with our results. A study of workers of a fila-
ment glass fiber plant in UK identified 7 cases who had
work-related asthma in serial PEF measurements, but was
not able to identify the causal agent in challenge testing
[27]. An investigation of a fiberglass wool insulation pro-
duction facility in USA was prompted because of high
prevalence of wheezing and use of asthma medication
among employees, but these problems seemed to be
related to endotoxin from bacteria growing in the recircu-
lating wash water [28]. Kilburn and co-workers [29] stud-
ied clinically 284 workers from Sheet metal Workers'
International Association who had at least 20 years of
exposure to fiberglass. Nineteen percent of the study pop-
ulation reported throat irritation, 13% nose irritation and
10% chest burning. Spirometric lung function was
reduced in fiberglass-exposed workers compared to the
reference values. However, some of these study subjects
had also had exposure to asbestos and there was no con-
trol population for comparison to assess the risks of these
conditions.
Some studies have investigated mortality from non-malig-
nant respiratory disease in workers exposed to MMVF.
Chiazze and coworkers [30] conducted a case-control
study among workers employed at the Owens-Corming
Fiberglass plant in Ohio and reported a non-significantly
increased adjusted OR 1.50 (95% CI 0.55–4.08) in rela-
tion to cumulative exposure to >300 fibers/ml. A longitu-
dinal study of MMVF workers from 13 factories in seven
countries followed 11,373 workers and found a slightly
increased mortality from bronchitis, emphysema and
asthma among glass wool workers with a SMR 1.12 (95%
CI 0.82–1.49) [31].
Workers are also exposed to glass microfibers through
direct contact with the skin. Skin symptoms, such as itch-
ing, and dermatitis are rather consistently reported in rela-
tion to occupational exposure to glass microfibers or
other MMVFs in case reports, studies of individual facto-
ries, and registry-based studies [10-12,32]. Glass fibers
and sensitizers, such as phenol-formaldehyde resin, have
been identified as causes for individual cases. According
to the Finnish Register of Occupational Diseases, the rate
of skin diseases due to MMVF was highest in insulation
workers with an annual incidence of 9.1 per 100,000Environmental Health 2009, 8:36 http://www.ehjournal.net/content/8/1/36
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employed workers [11]. Only one previous study assessed
the risk of skin diseases related to glass microfiber expo-
sure. A Japanese cross-sectional study of 148 workers from
fiberglass reinforced plastics factories [12] found signifi-
cantly increased risk of work-related skin problems with
OR ranging between 4.10 and 4.69. Thus, the Japanese
study is consistent with our study that shows an OR of
3.89 for skin symptoms in factory workers compared to
office workers.
Conclusion
This study provides evidence that exposure to glass micro-
fibers increases the risk of both respiratory and skin symp-
toms, increasing exposure showing exposure-response
relation with breathlessness and skin symptoms. The risks
of wheezing and asthma were also increased in relation to
glass microfiber exposure, although not statistically signif-
icant, probably because of a small number of asthmatics
in our study population. Exposure routes via inhalation
and direct contact with skin could both be of importance.
Glass microfibers are considered irritant, but some sensi-
tizing chemicals, such as formaldehyde, are also used in
the manufacturing processes. Exposure to these sensitizers
increased the risk of cough and nasal symptoms. The
results suggest that occupational exposure to glass micro-
fibers is related to non-malignant adverse health effects,
and that implementing exposure control measures in this
type of industries could protect the health of employees.
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